Literature DB >> 12149147

Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors.

Jun-Ichi Akahira1, Takashi Suzuki, Kiyoshi Ito, Chika Kaneko, Andrew D Darnel, Takuya Moriya, Kunihiro Okamura, Nobuo Yaegashi, Hironobu Sasano.   

Abstract

Human epithelial ovarian neoplasm is well-known to be sex steroid-related, but the possible biological significance of progesterone actions in these tumors remains controversial. In this study, we examined the differential expression patterns of the two progesterone receptor (PR) isoforms, PRA and PRB, using immunohistochemistry and real-time quantitative RT-PCR in normal and neoplastic ovarian tissues, and in cell lines derived from a normal ovarian surface epithelium and an ovarian epithelial carcinoma in order to further elucidate the possible involvement of progesterone in the development of ovarian neoplasms. The median H scores for PR isoforms in normal (n = 8), benign (n = 10), borderline (n = 8) and malignant (n = 24) ovarian tissues were as follows; PRA: 194.0, 171.0, 49.5, 0 (P < 0.05), and PRB: 175.0, 180.5, 251.5, 168.5, respectively. In ovarian cancer cell lines (OVCAR-3 and Caov-3), the PRB / PRAB mRNA ratio was increased by 17beta-estradiol, both time- and dose-dependently. However, this ratio was unaltered following the addition of 17beta-estradiol in a normal ovarian epithelial cell line (NOV-31). Immunoblotting analysis demonstrated that PRB protein expression was markedly up-regulated in OVCAR-3, whereas the PRA and PRB isoforms both appeared to be increased in NOV-31. These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149147      PMCID: PMC5927076          DOI: 10.1111/j.1349-7006.2002.tb01323.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  45 in total

Review 1.  Physiological action of progesterone in target tissues.

Authors:  J D Graham; C L Clarke
Journal:  Endocr Rev       Date:  1997-08       Impact factor: 19.871

2.  Cloning of the chicken progesterone receptor.

Authors:  J M Jeltsch; Z Krozowski; C Quirin-Stricker; H Gronemeyer; R J Simpson; J M Garnier; A Krust; F Jacob; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 3.  Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology.

Authors:  M Dietel; S Hauptmann
Journal:  Virchows Arch       Date:  2000-05       Impact factor: 4.064

4.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

Review 5.  Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations.

Authors:  A Kauppila
Journal:  Acta Obstet Gynecol Scand       Date:  1984       Impact factor: 3.636

6.  Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.

Authors:  J D Ahlgren; N M Ellison; R J Gottlieb; F Laluna; J J Lokich; P R Sinclair; W Ueno; G L Wampler; K Y Yeung; D Alt
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

7.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.

Authors:  S P Langdon; H Gabra; J M Bartlett; G J Rabiaz; R A Hawkins; A L Tesdale; A A Ritchie; W R Miller; J F Smyth
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

9.  Plasma level of estradiol in patients with ovarian malignant tumors.

Authors:  C G Mählck; T Bäckström; O Kjellgren
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  21 in total

1.  Ovarian surface epithelium receptors during pregnancy and estrus cycle of rats with emphasis on steroids and gonadotropin fluctuation.

Authors:  Salina Y Saddick
Journal:  Saudi J Biol Sci       Date:  2014-03-13       Impact factor: 4.219

Review 2.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

3.  Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.

Authors:  Pengming Sun; Jalid Sehouli; Carsten Denkert; Alexander Mustea; Dominique Könsgen; Ines Koch; Lihui Wei; Werner Lichtenegger
Journal:  J Mol Med (Berl)       Date:  2005-03-16       Impact factor: 4.599

4.  Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events.

Authors:  Nathan J Charles; Peter Thomas; Carol A Lange
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

5.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

Review 6.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

7.  Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.

Authors:  William J Murdoch; Edward A Van Kirk; Dale D Isaak; Youqing Shen
Journal:  Gynecol Oncol       Date:  2008-05-20       Impact factor: 5.482

8.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

9.  Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.

Authors:  Laura J Mauro; Megan I Seibel; Caroline H Diep; Angela Spartz; Carlos Perez Kerkvliet; Hari Singhal; Elizabeth M Swisher; Lauren E Schwartz; Ronny Drapkin; Siddharth Saini; Fatmata Sesay; Larisa Litovchick; Carol A Lange
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 10.  A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen Gallus gallus.

Authors:  Purab Pal; Kara Nicole Starkweather; Karen Held Hales; Dale Buchanan Hales
Journal:  Comp Med       Date:  2021-07-29       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.